Dossier
antitrust risks
Coverage of antitrust risks in the Nexus archive.
AstraZenecaorganization1Bristol Myers Squibborganization1patent clifftopic1investorstopic1shareholderstopic1Bernsteinorganization1prediction-market operational consolidationtopic1M&A wavetopic1exchange infrastructuretopic1clearing infrastructuretopic1brokerage infrastructuretopic1regulatory riskstopic1
- AstraZeneca investors raise concerns over mega-merger talks
AstraZeneca investors are expressing concerns about a potential $400 billion merger with Bristol Myers Squibb, citing risks related to an impending patent cliff and antitrust challenges.
- Prediction-market operational consolidation could spur M&A wave: Bernstein
Bernstein reports that platforms are consolidating exchange, clearing, and brokerage infrastructure in-house, potentially leading to a wave of M&A deals while raising antitrust and regulatory risks.